Published on 18 Oct 2023 on Zacks via Yahoo Finance
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
Biomea Fusion, Inc. BMEA, a clinical-stage company, announced dosing the first patient in its early-stage study of BMF-500 in the treatment of adult patients with relapsed or refractory acute leukemia.
BMF-500 is the company’s investigational covalent FLT3 inhibitor developed using the proprietary FUSION System.
The phase I COVALENT-103 study is evaluating the safety and efficacy of twice-daily oral BMF-500 as a monotherapy in adult patients with relapsed or refractory acute leukemia with FLT3 wild-type and FLT3 mutations.